참고문헌
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. https://doi.org/10.3322/caac.21208
- Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010 [Internet]. National Cancer Institute. Bethesda (MD): National Cancer Institute; [cited 2013 Apr]. Available from: http://seer.cancer.gov/archive/csr/1975_2010/
- Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057
-
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
$^{(R)}$ ). Gastric Cancer. Version 1. 2014 [Internet]. Fort Washington (PA): NCCN; [cited 2014 Jul 23]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. - Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 Suppl 3:49-58. https://doi.org/10.1634/theoncologist.10-90003-49
- National Cancer Institute. The Surveillance, Epidemiology, and End Results: Population Characteristics. 2013 [Internet]. Bethesda (MD): National Cancer Institute; [cited 2013 Dec 31]. Available from: http://seer.cancer.gov/registries/characteristics.html.
- Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl):IV-3-18.
- Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(8 Suppl):IV-55-61.
- Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40(8 Suppl):IV-104-117.
- Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40(8 Suppl):IV-43-48.
- Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicarelinked data. Med Care 2002;40(8 Suppl):IV-49-54.
- Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002;20:173-178. https://doi.org/10.1200/JCO.20.1.173
- Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006;107:2581-2588. https://doi.org/10.1002/cncr.22316
- Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-1240. https://doi.org/10.1016/j.jclinepi.2008.01.006
- Lang K, Marciniak MD, Faries D, Stokes M, Buesching D, Earle C, et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2009;12:481-488. https://doi.org/10.1111/j.1524-4733.2008.00472.x
- Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-4978. https://doi.org/10.1200/JCO.2004.05.031
- Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008;14:297-306.
- Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res 2011;31:3543-3554.
- Javle M, Hsueh CT. Updates in gastrointestinal oncology: insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9. https://doi.org/10.1186/1756-8722-2-9
- Kilickap S, Yalcin S, Ates O, Tekuzman G. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting. Hepatogastroenterology 2011;58:208-212.
- Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9 Suppl 2:9-15. https://doi.org/10.1634/theoncologist.9-suppl_2-9
- Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997. https://doi.org/10.1200/JCO.2006.06.8429
- Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14-18. https://doi.org/10.1007/s10120-005-0351-6
- Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007;37:936-941. https://doi.org/10.1093/jjco/hym123
- Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013;24:2850-2854. https://doi.org/10.1093/annonc/mdt351
- Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008;61:631-637. https://doi.org/10.1007/s00280-007-0516-6
- Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 2004;27:477-480. https://doi.org/10.1097/01.coc.0000136018.81814.79
- Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314. https://doi.org/10.1016/j.ejca.2011.06.002
- Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol 2009;15:2689-2692. https://doi.org/10.3748/wjg.15.2689
- Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518. https://doi.org/10.1200/JCO.2011.39.4585
- Bachmann M, Peters T, Harvey I. Costs and concentration of cancer care: evidence for pancreatic, oesophageal and gastric cancers in National Health Service hospitals. J Health Serv Res Policy 2003;8:75-82. https://doi.org/10.1258/135581903321466030
- Elixhauser A, Halpern MT. Economic evaluations of gastric and pancreatic cancer. Hepatogastroenterology 1999;46:1206-1213.
- Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007;99:14-23. https://doi.org/10.1093/jnci/djk001
- Sherman KL, Merkow RP, Shah AM, Wang CE, Bilimoria KY, Bentrem DJ. Assessment of advanced gastric cancer management in the United States. Ann Surg Oncol 2013;20:2124-2131. https://doi.org/10.1245/s10434-013-2953-2
- Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, et al. Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer 2015;18:360-367. https://doi.org/10.1007/s10120-014-0375-x
피인용 문헌
- Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data vol.1, pp.None, 2015, https://doi.org/10.1200/cci.17.00002
- Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments vol.26, pp.7, 2018, https://doi.org/10.1007/s00520-018-4065-9
- Targeted literature review of the global burden of gastric cancer vol.12, pp.None, 2015, https://doi.org/10.3332/ecancer.2018.883
- Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart Review vol.2, pp.2, 2015, https://doi.org/10.1007/s41669-017-0043-2
- Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity vol.155, pp.3, 2015, https://doi.org/10.1053/j.gastro.2018.05.026
- Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer vol.23, pp.1, 2020, https://doi.org/10.1007/s10120-019-01008-9
- Impact of Physical and Functional Limitations on Health Care Utilization in Older Cancer Survivors: A Medicare Current Beneficiary Survey vol.32, pp.9, 2015, https://doi.org/10.1177/0898264319872309
- Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer vol.20, pp.None, 2015, https://doi.org/10.1186/s12876-020-01232-z
- Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer vol.17, pp.3, 2015, https://doi.org/10.2217/fon-2020-0516